Today's announcements are the first hints of serious developments on the commercial side. Commercial partners needed to see how the first clinical trials went before any more discussions. Same applies to potential institutional investors. That's why it made sense to have the consolidation after the first phase trials were successfully completed. It's a high risk game, so don't risk too much, but when you buy PAA you are spreading that risk over 3 medications that are at an advanced stage of development and a growing specialist chemical compound developer that has now sold its services in 33 countries. It will only take one good announcement or results from the upcoming phase 2 or 3 trials and PAA could be off to the races. To quote the good captain, PATIENCE, PATIENCE, PATIENCE.
Cheers
DYOR
Today's announcements are the first hints of serious...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
-0.005(2.50%) |
Mkt cap ! $87.89M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.8¢ | 19.5¢ | $47.34K | 241.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 465889 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 792103 | 8 |
View Market Depth
| Last trade - 15.38pm 10/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |